Following the FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) in September, the field of gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma is buzzing when it comes to immunotherapies.
http://www.onclive.com/web-exclusives/expert-discusses-continued-growth-of-immunotherapy-in-gastricgej-cancer
Expert Discusses Continued Growth of Immunotherapy in Gastric/GEJ Cancer